Skip to main content
Menu

Posts tagged with "Drug Assays"

  • Drug Assays

    Drug Repurposing: How Often Does It Work?

    Here’s an article that will not be popular among some constituencies. It’s in a special issue of the Journal of Chemical Information and Modeling, devoted to how these disciplines have responded to the coronavirus pandemic. And in it, Aled Edwards of the Structural Genomics Consortium surveys past attempts at drug repurposing and arrive… Read More
  • Drug Assays

    Machine Learning On Top of DNA Encoded Libraries

    DNA-encoded libraries are a technique that many in the field should be familiar with, and they’ve come up many times here on the blog. The basic idea is simple: you build up a set of small molecules with some relatively simple synthetic steps, with plenty of branching at each stage. As a thought experiment, this… Read More
  • Covid-19

    The Order of Battle

    Among the many drug-discovery lessons that this pandemic is highlighting is the difficulty of meeting the challenges of a new target, a new pathogen, a new disease, or a new mechanism of action. When you look at the history of the drug industry, the typical time for an effective therapy to be developed from a… Read More
  • Current Events

    Omeprazole As An Additive For Coronavirus Therapy

    One of the notable things about the current pandemic is the way that all our modern biology and analytical techniques are on display. Molecular biology, structural biology, bioinformatics, technologies like cryo-EM structure determination, fast sequencing, protein interaction screening and more – this is a real-time look at how basic biomedic… Read More
  • Analytical Chemistry

    More on Screening For Coronavirus Therapies

    Time for a word about screening for new coronavirus drugs. Things have gone on long enough for quite a few groups to produce supplies of the various viral proteins and set up small-molecule screens against them. That’s no bad thing in itself, although it is a slow thing, a very slow thing by the standards… Read More
  • Current Events

    Hydroxychloroquine Update For April 6

    There’s a lot of news to catch up on, and to keep things straight I’ll divide the hydroxychloroquine part out into this post, and cover others in the next one. My previous reviews of the clinical data in this area are here. First up is this study from France. It’s another very small one, and… Read More
  • Current Events

    What the Coronavirus Proteins Are Targeting

    I wanted to mention this paper, which is one of the more comprehensive ones on the idea of repurposing existing drugs against the coronavirus. It’s a large multicenter team that clearly did a lot of very fast coordination to produce these results. What they’ve done is looked at the complete suite of proteins produced by… Read More
  • Analytical Chemistry

    Only Connect

    Anyone who’s done fragment-based drug design (especially) or who has just looked at a lot of X-ray crystal structures of bound ligands will be able to back up this statement: if you sit down with a series of such structures, all bound to the same site, it is very, very difficult to rank-order them in… Read More
  • Analytical Chemistry

    More on Covalent Compounds, And Covalent Fragments

    At a previous company some years back, I was interested in getting a “covalent fragment” collection going, and did to a small extent. It got screened against some antibacterial targets, but never became all that popular. That was partly because fragment-based screening was a younger field, and combining it with covalent drug discovery … Read More
  • Analytical Chemistry

    Fragment Binding, All the Way Down

    I remember the time before anyone did fragment-based drug discovery, when I heard high-micromolar binding ligands described as “carpet lint” or “stuff from the bottom of your shoe”. And you only heard then when the assays themselves even read out at that level, which certainly wasn’t a given. When I started, a suggesti… Read More